IP Library Granted Patent US 11,534,451
Granted Patent B2
US 11,534,451 · App. 16/064,192 · Granted Dec 27, 2022

Nucleic acid oligomers and uses therefor

Inventors: Derek Richard (Ferny Grove, AU); Kenneth O'Byrne (Cleveland, AU); Laura Croft (Morningside, AU); Sam Beard (Rochedale South, AU)
Assignee: REPLUCA PTY LTD
A61K31/7125A61K45/06A61P35/00C12N15/113C12N15/115C12N2310/11C12N2310/315C12N2310/321C12N2310/346
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,534,451
App. No.
16/064,192
Granted
Dec 27, 2022
Kind
B2
Abstract

Disclosed are nucleic acid oligomer compounds and to their use in compositions and methods for inhibiting proliferation, survival or viability of cancer cells including prostate, lung, pancreatic, breast, cervical and bone cancer cells.

Claims (7)

1. A method for inhibiting proliferation, survival or viability of a tumor cell, the method comprising introducing into the tumor cell a nucleic acid oligomer of up to 29 nucleobases in length, and comprising the nucleobase sequence set forth in SEQ ID NO:1.

2. The method of claim 1 , wherein the tumor cell is selected from the group consisting of a cervical tumor cell, a bone tumor cell, a prostate tumor cell, a breast tumor cell, a lung tumor cell and a non-small cell lung tumor cell.

3. The method of claim 1 , wherein the oligomer is not complexed with a complexing agent that facilitates uptake of the oligomer into the tumor cell.

4. The method of claim 1 , wherein the oligomer is complexed with a complexing agent that facilitates uptake of the oligomer into the tumor cell.

5. The method of claim 4 , wherein the complexing agent is a cationic lipid, peptide, polypeptide or non-biological cationic polymer.

6. The method of claim 4 , wherein the complexing agent is a liposome.

7. A method for inhibiting proliferation, survival or viability of a tumor cell, the method comprising introducing into the tumor cell a nucleic acid oligomer consisting of the nucleobase sequence set forth in SEQ ID NO:1.

Assignments (3)
CHANGE OF NAME Recorded May 18, 2021
From: CARP PHARMACEUTICALS PTY LTD
To: REPLUCA PTY LTD
Reel/Frame 056269/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2021
From: QUEENSLAND UNIVERSITY OF TECHNOLOGY
To: CARP PHARMACEUTICALS PTY LTD
Reel/Frame 056002/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2018
From: RICHARD, DEREK; O'BYRNE, KENNETH; CROFT, LAURA; BEARD, SAM
To: QUEENSLAND UNIVERSITY OF TECHNOLOGY
Reel/Frame 047807/0764 →
Priority Claims (1)
AU 2015905380 · Dec 23, 2015 · national
Continuity (1)
Related Publication 20200230168A1 · Jul 23, 2020